Dissertation > Excellent graduate degree dissertation topics show

Intracoronary Versus Intravenous Administration of GP IIb/IIIa Inhibitor Improves Myocardial Reperfusion in STEMI Patients

Author: ZhangYouSheng
Tutor: ZhouXuChen
School: Dalian Medical University
Course: Internal Medicine
Keywords: Thrombus Aspiration Tirofiban With acute ST- segment elevation myocardial infarction
CLC: R542.22
Type: Master's thesis
Year: 2011
Downloads: 1
Quote: 0
Read: Download Dissertation


Objective: To explore the safety and effectiveness of comparison of intracoronary versus intravenous administration of the glycoprotein IIb/IIIa inhibitor improves myocardial microcirculation during primary percutaneous coronary intervention (PPCI)for acute ST-segment elevation myocardial infarction (STEMI).Methods: From 1st, 2009 to 12th 2010 total 177 consecutive patients according with ACC/AHH guidelines defined STEMI, confirmed thrombi lesions by coronary angiography and thrombus score remained >2 score after the aspiration by DIVER C.E catheter thrombus aspiration. The patients were randomized to intracoronary administration of Tirofiban (groupA, 92patients) and conventional intravenous administration Tirofiban(groupB, 85patients).GroupA: intra-infarct related artery (IRA) administration of 10μg/kg of Tirofiban 3min via DIVER C.E catheter, subsequently intravenous infusion of 0.1μg·kg-1·min-1 of Tirofiban for 6-8 hours after PPCI. Group B: intravenous administration of 10μg/kg of Tirofiban 3 minutes, subsequent intravenous infusion of 0.1μg·kg -1·min-1 of Tirofiban for 24-36 hour after PPCI. All of the patients received Aspirin 100mg/d, Clopidogrel75mg/d, and subcutaneously low molecular heparin (60 U/kg body weight) after PPCI. Factors as clinical general status, corrected TIMI frame count(CTFC), myocardial blush grade (MBG), ST-segment elevation resolution (STR, >70%) at 24-hour after PPCI, the peak of creatine troponin I (CTn-I), the Ratio of no-reflow/slow- flow, complications as haemorrhage, thrombocytopenia, and in-hospital/30 days major adverse cardiac event (MACE, cardiac death, repeat myocardial infarction and acute heart failure ) were evaluated.Results: There was no difference in baseline characteristics between two groups. Compared with group B, group A showed lower ratio no-reflow/slow-flow phenomenon (4.3% vs.14.1%, P=0.006). TIMI frame count (24.1±16.67 vs.26.67±18.34, P=0.004), MBG (2.03±0.32 vs.1.12±0.47, P=0.021), ST fall-after-rise >70% within 24 hours (67% vs.57%, P=0.003), and the peak of CTn-I (2.77±0.43 vs. 3.98±0.63, P=0.016) indicated that intracoronary Tirofiban may be helpful for myocardial reperfusion. The MACE of in-hospital/30 days follow-up (6.5% vs. 18.8%, P=0.001) were also lower in group A, especially in cardiac death (2.2% vs. 7.1%, P=0.001), repeat myocardial infarction (1.1% vs.3.5%, P=0.008) and acute heart failure (3.3% vs.8.2%, P=0.002). Major bleeding (1.1% vs.4.7%, P =0.003) was lower in group A and the thrombocytopenia was similar in both groups (2.2% vs. 3.5%, P=0.13).Conclusions: During PPCI for STEMI patients with big thrombus burden after aspiration methods, compared with intravenous administration, Intracoronary administration of Tirofiban may improve myocardial reperfusion, decreasing no-reflow phenomenon, reducing hemorrhages events.

Related Dissertations

  1. Clinical Research of Tirofiban Application Intracoronary Artery and Vein During Percutaneous Coronary Intervention in Patients with Acute Myocardial Infartion,R542.22
  2. Glinicalstudy of Early Application of Tirofiban in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention,R541.4
  3. The Effect in Adherence Platelets with HUVECs and in Patients with AMI after PCI by Tirofiban,R542.22
  4. The Correlation of Tirofiban-modified Thromboelastography with Fibrinogen Level in Patients Undergoing Cardiopulmonary Bypass,R614
  5. Rapamycin - tirofiban combined prevention and treatment of drug-eluting stents and stent thrombosis after PCI Restenosis Study,R541.4
  6. The Observation of the Value of Tirofiban Hydrochloride in Patients with Acute Myocardial Infarction and No/slow Reflow Phenomena after Direct Percutaneous Coronary Intervention.,R542.22
  7. Clinical Study of Heart Function Effect in AMI Patients with DES and Tirofiban,R542.22
  8. Serial Study of Improving Myocardial Tissue Perfusion in Emergent Percutaneous Coronary Intervention in Acute Myocardial Infarction,R542.22
  9. Percutaneous coronary intervention intracoronary application of tirofiban clinical observation,R541.4
  10. The Investigation on Application of Thrombus Aspiration in Primary Percutaneous Coronary Intervention for Patients with ST-elevation Acute Myocardial Infarction,R542.22
  11. Thrombectomy joint GP Ⅱ b / Ⅲ a receptor antagonist effect of thrombus burden lesions observed,R541.4
  12. Tirofiban in patients with coronary heart disease after interventional treatment of inflammation and endothelial growth factor,R541.4
  13. Tirofiban in high-risk NSTE-ACS coronary intervention timing of application,R541.4
  14. Tirofiban on porcine myocardial infarction after reperfusion Protection,R541.4
  15. The Influence of Tirofiban on the Inflammatory Factors and Myocardial Injury in Patients with Acute Myocardial Infarction after PCI,R542.22
  16. Clinical Effects and Safety Evaluation of Delayed PCI Combined with Platelet Glycoprotein Ⅱb/Ⅲa Blockade Therapy in Patients with Acute Myocardial Infarction,R542.22
  17. Tirofiban hydrochloride clopidogrel resistance in patients with acute coronary syndrome, coronary interventional treatment efficacy and safety evaluation,R541.4
  18. Tirofiban hydrochloride in acute ST-segment elevation myocardial infarction in patients with primary percutaneous coronary intervention after coronary flow and myocardial infarct size effects in clinical studies,R542.22
  19. The Effects of Tirofiban on Platelet Aggression Radio, Activated Clotting Time and Serum Antithrombin Ⅲ in Patients with Acute Coronary Syndrome after Undergoing Percutaneous Coronary Intervention,R541.4
  20. Tirofiban used in ACS patients undergoing PCI, different timing of efficacy and safety,R541.4

CLC: > Medicine, health > Internal Medicine > Heart, blood vessels ( circulatory ) disease > Heart disease > Myocardial diseases > Myocardial infarction
© 2012 www.DissertationTopic.Net  Mobile